Checklist: Preparing your manuscript for publication

To minimize publication time, we ask authors to note the following manuscript guidelines. Please remember that failure to provide the text and graphics in the prescribed formats can lead to requests for new materials. Thus, to avoid any delays in the production of your article, we suggest you go through this entire checklist carefully.

GENERAL HANDLING OF THE FILES

✓ The main text should be submitted as a **Microsoft Word document**

✓ Submission of the **final/revised manuscript** should occur through **Editorial Manager**: www.editorialmanager.com/chemselect/

✓ Naming files: Files should start with "slct.", followed by the manuscript number and a name which allows an easy and unambiguous identification of the file.

LANGUAGE

Language polishing

✓ Authors should note that **no language polishing is provided** for manuscripts accepted by *ChemistrySelect*.

✓ To ensure typographical errors and grammar/language issues are addressed, authors are encouraged to have a native or fluent English speaker read over the manuscript.

✓ If you would like help with English language editing, or other article preparation support, Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, and figure formatting at www.wileyauthors.com/eeo/preparation. You can also check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript at www.wileyauthors.com/eeo/prepresources.

Spelling

✓ Spelling can be British or American English, but **consistency should be maintained** within a manuscript.

✓ Use a simple, clear style and avoid jargon.

✓ Please follow IUPAC guidelines (see IUPAC chemical nomenclature recommendations), e.g. it should be "Sulfur", not "Sulphur".

Please note, the Editorial Office cannot be held responsible should any typos or language errors become evident upon publication. The journal will only publish corrigenda to correct scientific errors or factual mistakes.

MANUSCRIPT SECTIONS

Order

✓ **Full Papers:** Title – Authors – Affiliations – Abstract – Main Text (Results & Discussion section and the Conclusion paragraph) with all schemes/figures/tables together with their captions at the appropriate place – Supporting Information Summary – Acknowledgements – Keywords – Reference List – Table of Contents

✓ **Communications:** Title – Authors – Affiliations – Abstract – Main Text (with all schemes/figures/tables together with their captions at the appropriate place) – Supporting Information Summary – Acknowledgements – Keywords – Reference List – Table of Contents

✓ **Reviews:** Title – Authors – Affiliations – Abstract – Author Biographies – Main Text (with all schemes/figures/tables together with their captions at the appropriate place) – Acknowledgements – Keywords – Reference List – Table of Contents

For further information about the manuscript types (e.g. manuscript length) please refer to the Notice to Authors in our Author Guidelines.

Title

✓ The Title should be as succinct and informative as possible with **no more than 150 characters** (excl. spaces)

✓ The first letters of all words, except coordinating conjunctions, articles and prepositions should be capitalized.

✓ The use of words such as “New”, “Novel”, and “First” as well as chemical formulae should be avoided.

✓ Please don’t include references.

Author line

✓ **Academic titles (“Dr.”/”Prof.”)**, full first names and surnames need to be listed (in the same order).

✓ An **asterisk (*)** indicates each corresponding author.

✓ **ORCID (Open Researcher and Contributor ID)**

- Please note that ORCID registration and authentication is required for submission of the manuscript.
- Registry that provides a unique digital identifier for authors
- Registration is free.
- For further information, please see orcid.org and your funding agency guidelines for details.

Affiliations

✓ **All Author names** (first names as initials) and the **Affiliation addresses** (division name, institute name, institute full address including street, city, postal code and country) should be listed.

✓ Corresponding authors should have an **email address** listed.

✓ Author names belonging to the same group/division can be bunched together.

✓ If authors contributed to the work equally, please add an additional footnote.

Abstract

✓ Please keep it brief (**1000 characters excl. spaces**)

✓ For **Full Papers and Communications**: Reflection of the content of the work (motivation of the work, the methods applied, the key results and the conclusions drawn).

✓ For **Reviews**: Summary of the topic under discussion, the main findings and arguments.

✓ The Abstract **must stand alone** (no hints to graphical elements in the main text or references) as this section will be found and read independently in databases.

✓ The integration of **compound numbers and abbreviations** is permitted but **must be defined** when first used.

Author Biographies (ONLY for Reviews)

✓ A short **professional biography (70–100 words)** and a **portrait-quality photograph** should be provided for each author who contributed to the manuscript.

Main Text

✓ **Full Papers/Research Articles** should be subdivided as follows:

- **Introduction:** It enables readers to become familiar with the subject and the importance of the results presented. Relevant references should be included.
- **Results and Discussion** may be combined or kept separate. These sections may be further divided by subheadings.
- **Conclusion:** the results should be summarized succinctly and with reference to the significance of the findings and, if appropriate, to the remaining challenges.

✓ **Communications** should not be divided into sections; however, technical methods can be given under a separate headline.

✓ **Reviews** should contain numbered sections, including amongst others an Introduction and a Summary & Outlook section, in which the achievements and new challenges of the subject are presented succinctly.

Supporting Information Summary

✓ For Communications and Full Papers, the complete Experimental Section (materials/procedures/analytical data, etc.) should be placed in the Supporting Information. As such, there should be a short paragraph between the Conclusion and the Acknowledgements, **summarizing what the readers can expect to see in the Supporting Information** (see section on "Supporting Information" below).

Acknowledgements

✓ Acknowledgements should be given for any support, e.g. financial.

✓ Affiliations should be included for people acknowledged.

✓ Please ensure that institute acronyms are defined.

Keywords

✓ A maximum of **five keywords** should be given in alphabetical order.

✓ At least two must come from the **core keyword list** https://application.wiley-vch.de/vch/journals/keyword.php (see link sequence "Author guidelines" – "Notice to Authors" on our homepage www.chemistryselect.org).

Reference List

✓ **Reference Numbers**

- References to literature in the main text should be typed in square brackets as superscripts after any punctuation.
- In the reference list, reference numbers are listed in square brackets (not as superscripts).
- Please format to [1,2] rather than [1],[2] and [1-5] rather than [1,2,3,4,5].

✓ **Style**

- **Author names** should be cited as follows: first name initial – surname – comma –next author (e.g. J. B. Smith, A. K. Burns, etc.). The penultimate and the last name should not be separated by "and", but just by a comma.
- Please mention all author names in the citation (**not "et al."**) if the number of authors is fewer than 20.
- Please **abbreviate journal names** according to the Chemical Abstracts Service Source Index
- In general, book and journal names need to be typed *in italics*, publication years in **bold style**, volume numbers *in italics* please. Furthermore, please provide the page number range.
- Do not use a comma between the journal abbreviation and the publication year.

- **Article titles shouldn't be provided** in the Reference list.
- Please separate composite references by a) …; b) …; c) … etc., not a…; b…; c… . They should be separated with semicolons.
- **DOI numbers** should be replaced with the appropriate volume and page numbers; if those are not available yet, the DOI number should be kept.
- When citing publications from **Angewandte Chemie**, please quote **both German and International Editions**. The page numbers of the German version can be found at the end of the article and in the annual index of International Editions.

✓ **Please make sure that all references are provided according to our house style which is correctly illustrated via the following examples:**

- **Journals:**

  [1] a) S. C. Stinson, *Chem. Eng. News* **1998**, *76*, 57-73; b) B. Krebs, H. U. Hürter, *Acta Crystallogr. Sect. A* **1981**, *37*, 163.

  [2] H. J. Ache, *Angew. Chem.* **1989**, 101, 1-21; *Angew. Chem. Int. Ed.* **1989**, *28*, 1-20.

- **Books:**

  [1] E. Wingender, *Gene Regulation in Eukaryotes*, VCH, Weinheim, **1993**, p. 215.

  [2] T. D. Tullius in *Comprehensive Supramolecular Chemistry, Vol. 5* (Eds.: J. L. Atwood, J. E. D. Davies, D. D. MacNicol. F. Vögtle, K. S. Sulick), Pergamon, Oxford, **1996**, pp. 317-343.

- **Patents:**

  [1] a) H. Behre, M. Dockner, A. Klausener, (Bayer AG, Leverkusen, Germany), Int. PCT Pub. No. WO/2001/077061A1, **2001**.

- **Programs:**

  [2] M. J. Frisch, G. W. Trucks, H. B. Schlegel, … (**all authors need to be listed for programs, please don't use "et al."**) …, D. J. Fox, Gaussian 09, Revision E01 ed., Gaussian, Inc., Wallingford CT, USA, **2009**.

- **Theses:**

  [3] A. Student, PhD thesis, University of Newcastle (UK), **1991**.

- **Online Articles:**

  [1] S. Novick, "Biography of Rotational Spectra for Weakly Bound Complexes" to be found under http://www.wesleyan.edu/chem.bios/vdw.html, **1999**.

- **Collections:**

  [1] A Kleemann, K. Drauz, J. Engel, B. Kautscher, E. Wünsch, *Proc. 4th Akabori Conf.* (Shizuoka, Japan) **1991**, pp. 96-101.

Table of Contents

The Table of Contents section should consist of **two essential parts:**

✓ A short **running text** containing 60-80 words (or 350 characters, excl. spaces) with an eye-catching headline

- The text should refer to the figure supplied
- Key findings or concepts should be highlighted
- Repetition/paraphrasing of title, abstract or experimental details should be avoided

✓ An eye-catching **colour graphic**

- Final size: 5 cm tall x 5.5 cm wide or 2.5 cm tall x 11.5 cm wide
- Sans serif font, sized 6-7 points
- Complex schemes or diagrams should be avoided and text in the picture should be restricted to a minimum.

For examples of appropriate Table of Contents, please have a look at the Wiley Online Library https://onlinelibrary.wiley.com/journal/23656549

SUPPORTING INFORMATION (SI)

Please note, the author bears full responsibility for the content of the SI.

General Content

✓ All information should be provided in **English**.

✓ **The SI should not have a cover page** (no article title, no author names/affiliations). The typesetters will prepare a standard cover page for the SI.

✓ A **Table of Contents** is needed on page 1, outlining any sections contained therein and additional files available.

✓ The detailed **Experimental Section** should be found in the SI as the first section after the Table of Contents.

✓ Graphics that are part of the SI should have a separate numbering scheme and sequence (typically Figure S1, S2, etc.; Scheme S1, S2, etc., same for tables).

✓ In the main text, when citing graphics/tables/procedures included in the SI, it should be explicitly mentioned that contents of the Supporting Information are discussed, e.g. "... seen

in Figures S2-S3 in the Supporting Information"

✓ The SI should **not include crystallographic data** that are available from CCDC or FIZ (see section "Crystallographic Data").

Experimental Section

✓ Important for the repetition of your work by other scientists.

✓ Should be written in past tense

Ensure that detailed protocol descriptions (reagents, amounts, reaction times, temperatures, etc.), instruments, product characterization and physical data are provided:

Equipment and general conditions:

✓ Should be described at the beginning of the experimental section

✓ Quantities of reactants, solvents, etc. should be included in parentheses rather than in the running text, e.g. "triphenylstannyl chloride (0.964 g, 2.5 mmol) in toluene (20 mL)"

✓ Please use chemical formulae for common compounds instead of compound names, e.g. $CHCl_3$ instead of "chloroform".

✓ Indicate all solvent systems used, e.g. EtOAc/MeOH 1:2 as well as volumes and number of extractions, e.g. "extracted with $CHCl_3$ (3×5 mL)" for purification or extraction steps.

✓ Description of acidity: either pH2 or pH>2/pH<2 is preferred, not pH=2.

✓ Physical data: Please quote with decimal points and negative exponents, e.g. 25.8 $JK^{-1}mol^{-1}$

✓ For instruments, please indicate the model, the manufacturer's name, city and country.

Identification of new compounds:

✓ Please fully characterize new compounds by appropriate analytical methods (^{1}H NMR, ^{13}C NMR, X-ray crystallography, mass spectrometry, elemental analysis, sequencing data for biomolecules)

Purity of new compounds:

✓ Please ensure that the purity is verified to an acceptable accuracy.

✓ The application of one or more of the following techniques is required: HPLC, LC-MS, electrophoresis techniques, elemental analysis, NMR, etc.

Physical data:

✓ should be given in the following order for each prepared compound:

1. Physical characteristics (color, state): e.g., yellow needle-like crystals

2. Mass and yield: e.g., 109 mg, 95%
3. Thin-layer chromatography data/retention factor: e.g., R_f=0.38 ($CHCl_3$/MeOH 9:1)
4. Melting/boiling point: e.g., mp: 90.2–91.2 °C
5. Optical rotation: e.g., $[\alpha]_D^{20}$=–13.5 (c=0.2 in acetone)
6. Refractive index: e.g., n_D^{20}=1.460
7. ^{1}H NMR (peak, multiplicity, coupling constant, equivalent nuclei, assignment if known): e.g., ^{1}H NMR (200 MHz, [D_8]THF, 25 °C, TMS): δ=7.64–7.48 (m, 6 H; Ar–H), 1.33 ppm (q, J=8 Hz, 2 H; CH_2)
8. ^{13}C NMR (peak, assignment if known): e.g., ^{13}C NMR (75 MHz, $CDCl_3$, 25 °C, TMS): δ=72.5 (CCH), 26.8 ppm (CH_3)
9. IR absorptions (peak, assignment if known): e.g., IR (KBr): $\tilde{\nu}$=1780, 1790 cm^{-1} (C–O)
10. UV/Vis absorptions (peak, extinction coefficient): e.g., UV/Vis (*n*-hexane): λ_{max} (ε)=320 (5000), 270 nm (12000 mol^{-1} dm^3 cm^{-1})
11. Fluorescence excitation and emission: e.g., fluorescence (CH_2Cl_2): λ_{ex}=435.5 nm, λ_{em}=659.726 nm
12. Low-resolution mass spectrum: e.g., MS (EI, 70 eV) *m/z* (%): 173 (32), 171 (100) [*M*+H]$^+$
13. High-resolution mass spectrum: e.g., HRMS (ESI) *m/z* [*M*+Na]$^+$ calcd. for $C_{32}H_{47}NO_5$: 548.3352, found: 548.3331
14. Elemental analysis: e.g., Anal. calcd. for $C_{20}H_{32}N_2O_5$: C 63.14, H 8.48, N 7.36, found: C 62.88, H 8.41, N 7.44

✓ The data should be written in one paragraph, consistently formatted according to the journal style

✓ The data sets should be separated by semicolons please.

✓ **If a compound is not available for complete analysis (e.g. unstable, insufficient quantities) the exact relative molecular mass obtained from a high-resolution mass spectrum and clean NMR spectra must be supplied as a minimum requirement.**

✓ **Computational methods should likewise be presented.**

Additional Files in the SI

✓ **Animated multimedia applications, films, program scripts, datasets etc.** should be uploaded via Editorial Manager as SI.

✓ Begin all **file names** with "slct_201900001_SI-" (e.g., slct_201900001_SI-main_doc.pdf,

slct_201900001_SI-movie_1.mov, slct_201900001_SI-database_1.xls).

✓ To submit **multimedia files that exceed 5 MB in size**, please save them on a web server (e.g. publicly accessible institution server, Dropbox), but **do not link to them.** Send us the URL so we can download the files and make them available to our typesetters.

✓ Please use suitable **compression technology** to avoid exceedingly large movie files (>10 MB).

✓ Make sure that your movies are saved in a **common format** (e.g. MPEG, AVI, QuickTime, GIF) that can be played on at least two different computer platforms (out of Windows/MacOS/Linux). **Open formats are highly encouraged.**

TEXT FORMATTING

Abbreviations and acronyms:

✓ should be used sparingly and consistently.

✓ Where they first appear in the text, the complete term - apart from the most common acronyms such as NMR, IR, and tBu - should also be given.

✓ Common abbreviations for formulas can be used such as Me, Pr, Bu, Ph. Only in this case are prefixes such as *iso*-, *n*-, *tert*- written as a single italic letter without a dash: *i*Pr, *n*Bu, *t*Bu (e.g. *n*BuLi, but *n*-butyllithium; *n*Oct, but *n*-C_8H_{17}).

Compound numbers:

✓ In ascending order

✓ In bold typeface and Arabic numbers

✓ Do not use extremely long compound names or computer programs to generate elaborate systematic names

✓ For the sake of clarity, general descriptors such as compound 1, dendrimer 2, or alcohol 3 are recommended for the body text, reserving longer IUPAC nomenclature for the Experimental section in the SI.

Equations:

✓ Equations should be prepared within the main text (e.g. using Equation Editor).

✓ The number of the equation should be put at the end of the formula,

e.g. A+B→C (1).

Formulae for coordination compounds:

✓ Please follow IUPAC recommendations.

General substituents:

✓ Indicated by R^1, R^2, **not** by R_1, R_2 (which means 2xR)

✓ Use the proper prime symbol, not a "floating comma" when necessary (R' not R').

Greek letters and special characters:

✓ Choose Character font "Symbol".

✓ Use the Greek letter mu (μ) for the prefix micro, **not** the Latin letter u.

Italics: The following elements need to be provided in italics please:

✓ Letters which symbolize physical quantities (e.g. *T* for temperature, *E* for energy, *n* for an unspecific number, etc.).

✓ Stereochemical information (*cis*, *Z*, *R*)

✓ Locants in compound names (*N*-acetylimidazole)

✓ Symmetry and space groups (C_{2v})

✓ Prefixes in formulae or compound names (*tert*-butyl, *p*-aminosalicylic acid)

✓ **Please do not italicize phrases such as "in vitro", "et al." and "in vacuo".**

Oxidation state:

✓ When used with names of elements, they should be typed in capital Roman numerals within parentheses (e.g. iron(II), tin(IV)).

✓ In combination with the element symbols they should be superscripted (e.g. Fe^{II}, not Ru(III) but Ru^{III}).

Physical data:

✓ Must be given in the Experimental section in the **Supporting Information** (see guidelines for the Experimental section above).

Physical numerical data:

✓ Should be written with decimal points (**not commas**) and negative exponents, e.g. 25.8 $JK^{-1}mol^{-1}$.

Small Capitals font style:

✓ Used for stereochemical assignments (D- and L-), molar (M), and normal (N).

✓ Procedure (for Microsoft programs): type the small letter, highlight it, open font settings, and click on "small caps".

Tables, Equations, Figures, Schemes:

✓ Please ensure a numerical order in the main text.

✓ Write the terms in full and start them with a capital letter.

✓ Use Arabic (not Roman) numbers

✓ E.g. Table 1, Eq. (1) or Equation (1), Figure 1, Scheme 1.

GRAPHICAL MATERIAL

The consistency of the graphics throughout the manuscript is the most important thing to remember when preparing the final versions for upload.

Types of graphics:

✓ **Schemes:** sequentially numbered diagrams for synthetic procedures/any process where steps need to be outlined; captions are required, see details below.

✓ **Figures:** all other forms of graphics (sequentially numbered); captions are needed, see details below

✓ For structure formulae please see “Structural Formulae” in the section “Graphical Material”.

✓ **Please note, we do not use “Charts”.**

Ideal scheme:



Ideal figure:



Figure 4. Circular dichroism (CD) spectra of **1** (1×10^{-5} M, green line) and **2** (1×10^{-5} M, blue line) in $CHCl_3$.

Preparing the graphics:

✓ **Position:**

- Graphics and their captions need to be properly integrated into the main text where discussed. The captions should be included directly below the schemes or figures
- Please use the insertion mode "in line with text" under the "wrap text" option.

✓ **Graphic sizes:** Graphics should be designed for a **one-column format (8.5 cm wide)** or **a two-column format (17.5 cm wide)**.

✓ **Figure labels:**

- Axis labels:
  - Should be written in sentence case/contain a standard abbreviation for the physical quantity in italic font (e.g. *A* for absorption, E_i for ionization energy, etc.)
  - Special abbreviations should be explained in the legend.
  - Units in normal lower-case letters and separated by spaces and forward slash.
  - Inverse units should not be written as fraction denominators, but rather using negative exponents.

- Examples: Concentration / ppm, Aggregation time / s, Wavelength / nm, V_{abs} / mL g^{-1}, E_{int} / kJ mol^{-1}

➢ Subfigures: Please place A), B), etc. in the upper left corner of the respective figure partition within the figure to indicate partitions of the graphic.

➢ Reaction sequences in schemes: Use Roman lower-case letters (e.g. a, b, c, etc.) centered above or beside the reaction arrows. Do not use I, ii, etc.

➢ Text style:

- Follow the guidelines mentioned above in the section "Text formatting" for any text provided in graphics.
- Preferred font: sans serif (Arial, Helvetica, Calibri, sized at 7-9 point).
- **Please ensure consistency of the font style and size** throughout the graphics in a manuscript. Should differences in font size be unavoidable, these should not exceed by 2 points.

✓ **Structure formulae:**

➢ Structure formulae are presented in figures, schemes or tables and should be drawn using the Wiley style when prepared in ChemDraw (see ChemDraw template in our Author Guidelines at www.chemistryselect.org).

➢ Each structure should be accompanied by a label/compound number.

➢ Please remove circles surrounding "+" or "–" charges in chemical structure drawings.

➢ Minus signs (–) are longer than a hyphen (-). The proper minus sign can be obtained by typing the code for an en-dash (Alt+0150) or by using the dash for the symbol font.

➢ For structural formulae, the line width should be at least 0.2 pt or 0.1 mm.

➢ The structures should be saved as high-resolution graphics.

✓ **Captions:**

➢ Figure captions: Please make sure that abbreviations are defined in the caption.

➢ Scheme captions: information about solvents, reagents, reaction conditions, reaction times and yields should be included in the caption.

✓ **Reporting statistical variance:**

➢ Numerical entries/data points on tables/graphics that have errors/error bars: It should be indicated in the caption or footnote what the values represent (e.g. "values represent the mean ± SD carried out for n=3 independent experiments performed in triplicate").

➢ If statistical tests have been carried out (e.g. t-test, ANOVA), these and the resulting *p*-values should also be indicated in the caption.

✓ **Computer-aided image enhancement:**

- Please ensure a clear relationship between the original data and the electronic images that result from those data.
- The form of the image modification must always be given in the figure captions.
- If computer-aided processing/modification is a fundamental part of the experimental work, then the respective procedure must be clearly described in the Experimental section in the Supporting Information (SI).

✓ **Reproducing or adapting previously published graphics:**

- **Make sure you have permission to use any graphics reproduced or adapted from other work.** Therefore, a license request on the original publisher's website is needed (Please see link Permission Request Form)
- The reference and the original copyright holders should be cited in the accompanying caption, e.g. "Reproduced with permission from Ref. [27]. Copyright 2009, American Chemical Society.".
- Please send each copyright as a PDF file, properly labeled with the corresponding figure and reference (e.g. Copyright_Fig2a_Ref27.pdf).

TABLES

✓ A table template is available within the word template (see Author Guidelines on our homepage www.chemistryselect.org). This formatting should be followed.

✓ Tables should begin with a header row containing the appropriate headers and units.

✓ No line breaks within a cell please. Each entry should be in its own cell instead.

✓ Structural formulas in tables need to be submitted integrated into the table.

✓ References to footnotes are in Roman lowercase letters set in superscripted square brackets, e.g. "Yield [%][a]"

"[a] Percent yield was determined by..."; footnotes contain information that is key to understanding the table completely (such as experimental conditions, statistical variance (see guidelines for Graphical Material above), definitions of acronyms, etc.).

CRYSTALLOGRAPHIC DATA

✓ Atomic coordinates and the associated experimental data should be deposited in the appropriate data bank (see below).

✓ **Please note that the data in the databanks must be released, at the latest upon publication of the article. We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released.**

✓ **For organic and organometallic compounds:**

- Send your data, including author and journal details, in CIF format to the **Cambridge Crystallographic Data Centre** (CCDC, 12 Union Road, Cambridge CB2 1EZ (UK)) using their web-based deposition system, which can be found under www.ccdc.cam.ac.uk/services/structure_deposit.

- The data will be assigned a registry number, which should be included with the following **standard text** in the manuscript: "CCDC-… contain(s) the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via https://www.ccdc.cam.ac.uk/structures/.

✓ **For inorganic compounds, elements, metals, minerals:**

- Send the data via the homepage of the **Fachinformationszentrum (FIZ) Karlsruhe**, www.fiz-karlsruhe.de/depositing_crystal_structures.html.

- The data should be deposited in electronic form (CIF format).

- You will be given a CSD number which should be included with the following **standard text** in the manuscript: "Further details of the crystal structure investigation(s) can be obtained from the joint CCDC/FIZ Karlsruhe online deposition service (https://www.ccdc.cam.ac.uk/structures/) on quoting the depository number CSD-…"

✓ **Crystallographic data for proteins and nucleic acids:**

- Before submitting your manuscript, send the data directly to the **Protein Data Bank (PDB)**. For details, please visit www.rcsb.org/pdb.

✓ **Sequence data for nucleic acids:**

- Before submitting your manuscript, send the data directly to **GenBank** (www.ncbi.nlm.nih.gov/) or the EMBL Nucleotide Sequence Database (www.ebi.ac.uk/embl/index.html).

✓ **Sequence data for proteins:**

- Before submitting your manuscript, send the data directly to **PIR** (pir.georgetown.edu/) or **SwissProt** (www.expasy.ch/sprot/sprot-top.html).

RELEVANT NOTICES:

Notice for Experiments with Animal Subjects

Manuscripts containing **animal experiments** must include a statement that permission was obtained from the relevant national or local authorities. The institutional committees that have approved the experiments must be identified and the accreditation number of the laboratory or of the investigator given where applicable. If no such rules or permissions are in place in the country where the experiments were performed, then this must also be clearly stated. Manuscripts with experiments with **human subjects** or **tissue samples** from human subjects must contain a disclaimer in the Experimental Section to state that informed, signed consent was obtained from either the patient or next of kin.

Notice to NIH Grantees

Your work was supported by grants from the US National Institutes of Health (NIH). Please note that on behalf of our authors who are NIH grantees, Wiley-VCH will deposit accepted manuscript materials in Pub Med Central (PMC); PMC may display the peer-reviewed manuscript 12 months after Wiley-VCH has published the article. By assuming this responsibility, we can ensure our authors are in compliance with this NIH mandate, and can make certain the appropriate version of the manuscript is deposited. We reserve the right to change or rescind this policy.